TheProfitWatch

BTAI - BioXcel Therapeutics, Inc. Common Stock

Day 1m 10m 60m PreMarket Market AfterHours Gap
2.7 -0.02 (-0.74%) --- --- 0.01 (0.37%) -0.01 (-0.37%) -0.03 (-1.11%) 0.0 (0.0%) 0.0 (0.0%)

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

Category: PHARMACEUTICAL PREPARATIONS
Market Period: AfterHours

Earnings & Ratios

Basic EPS:
-2.45
Diluted EPS:
-2.45
Basic P/E:
-1.0939
Diluted P/E:
-1.0939
RSI(14) 1m:
100.0
VWAP:
2.68
RVol:
0.7503

Events

Period Kind Movement Occurred At
1m Price decrease 1m 2.64 -0.03 (-1.12%) Oct 15 16:29
1m Price increase 1m 2.65 +0.03 (+1.2%) Oct 15 15:06
1m Price decrease 1m 2.68 -0.03 (-1.11%) Oct 15 09:30
1m Price decrease 1m 2.7 -0.03 (-1.1%) Oct 15 08:42

Related News